Restructuring Charges (Tables)

6 Months Ended

Dec. 31, 2016

Restructuring Cost and Reserve [Line Items]

Segment Reporting Disclosure [Text Block]

Net restructuring charges by segment are as follows:

	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

SEGMENT INFORMATION

We have three reportable segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).

• CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical testing that range from first-in-man through proof-of-concept studies) to Phase II-III and Phase IV, which we include in our PAREXEL Access product offering, formerly known as Peri/Post Approval Services. Our services include clinical trials management and biostatistics, commercialization, data management and clinical pharmacology, as well as related medical advisory, patient recruitment, clinical supply and drug logistics, pharmacovigilance, and investigator site services. We aggregate Early Phase and PAREXEL Access with Phase II-III due to economic similarities in these operating segments.

• PC provides technical expertise and advice in such areas as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance. It also provides a full spectrum of market development, product development and targeted communication services in support of product launch. Our PC consultants identify alternatives and propose solutions to address client issues associated with product development, registration, and commercialization.

• PI provides information technology solutions designed to help improve clients’ product development and regulatory submission processes. PI offers a portfolio of products and services that includes medical imaging services, ClinPhone^® RTSM, IMPACT^® clinical trials management systems (“CTMS”), DataLabs^® electronic data capture, web-based portals, systems integration, electronic patient-reported outcomes, and LIQUENT InSight® Regulatory Information Management (“RIM”) solutions.

We evaluate our segment performance and allocate resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are allocated and evaluated on a geographic basis. Accordingly, we do not include the impact of selling, general, and administrative expenses, depreciation and amortization expense, other income (expense), and income tax expense in segment profitability. We attribute revenue to individual countries based upon the revenue earned in the respective countries; however, inter-segment transactions are not included in service revenue. Furthermore, we have a global infrastructure supporting our business segments, and therefore assets are not identified by reportable segment.

Our segment results were as follows:

(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Service revenue
CRS	$	408.9	$	407.1	$	785.2	$	817.3
PC	54.6		41.4		109.6		80.7
PI	70.9		70.0		136.3		132.6
Total service revenue	$	534.4	$	518.5	$	1,031.1	$	1,030.6
Direct costs
CRS	$	284.5	$	274.4	$	546.6	$	561.9
PC	30.9		20.8		61.3		41.0
PI	35.5		37.3		70.7		72.8
Total direct costs	$	350.9	$	332.5	$	678.6	$	675.7
Gross profit
CRS	$	124.4	$	132.7	$	238.6	$	255.4
PC	23.7		20.6		48.3		39.7
PI	35.4		32.7		65.6		59.8
Total gross profit	$	183.5	$	186.0	$	352.5	$	354.9

Restructuring Charges by Segment [Table Text Block]

Net restructuring charges by segment are as follows:

	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

Schedule Of Charges Against The Restructuring Accrual

	Balance at		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			Balance at
	June 30, 2016								December 31, 2016
2015 Margin Acceleration Program
Employee severance	$	10.5	$	(0.5	)	$	(6.8	)	$	3.2
Facilities-related	7.1		0.8			(2.8		)	5.1
Pre-Fiscal Year 2012 Restructuring Plans
Facilities-related	0.1		—			—			0.1
Total	$	17.7	$	0.3		$	(9.6	)	$	8.4